The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Goldman Cuts Burberry; Redburn Cuts HSBC

Fri, 07th Sep 2018 09:33

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:----------FTSE 100----------GOLDMAN CUTS BURBERRY GROUP TO 'NEUTRAL' ('CONVICTION BUY LIST') - TARGET 2536 PENCE----------RBC RAISES BURBERRY GROUP PRICE TARGET TO 1875 (1750) PENCE - 'UNDERPERFORM'----------RBC INITIATES DCC WITH 'OUTPERFORM' - TARGET 9500 PENCE----------RBC CUTS BUNZL PRICE TARGET TO 1800 (1950) PENCE - 'UNDERPERFORM'----------BERENBERG CUTS SHIRE TO 'HOLD' ('BUY') - TARGET 5000 (4500) PENCE----------JPMORGAN RAISES MELROSE INDUSTRIES PRICE TARGET TO 285 (260) PENCE - 'OVERWEIGHT'----------REDBURN CUTS HSBC TO 'SELL' ('NEUTRAL')----------BARCLAYS RAISES ST JAMES'S PLACE PRICE TARGET TO 1456 (1387) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES RSA INSURANCE PRICE TARGET TO 696 (693) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PRUDENTIAL PRICE TARGET TO 2163 (2076) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES LEGAL & GENERAL GROUP PRICE TARGET TO 317 (311) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES DIRECT LINE PRICE TARGET TO 366 (361) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES AVIVA PRICE TARGET TO 610 (581) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES ADMIRAL GROUP PRICE TARGET TO 1997 (1939) PENCE - 'UNDERWEIGHT'----------HSBC RAISES CENTRICA PRICE TARGET TO 142 (130) PENCE - 'REDUCE'----------KEPLER CHEUVREUX RAISES ASTRAZENECA PRICE TARGET TO 6100 (5630) PENCE - 'BUY'----------JEFFERIES CUTS ASTRAZENECA PRICE TARGET TO 5975 (6200) PENCE - 'HOLD'----------JEFFERIES CUTS GLAXOSMITHKLINE PRICE TARGET TO 1725 (1775) PENCE - 'BUY'----------FTSE 250----------JPMORGAN CUTS GO-AHEAD GROUP PRICE TARGET TO 1420 (1421) PENCE - 'UNDERWEIGHT'----------JPMORGAN CUTS WEIR GROUP PRICE TARGET TO 2060 (2200) PENCE - 'OVERWEIGHT'----------BARCLAYS CUTS WEIR GROUP PRICE TARGET TO 2500 (2600) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES PHOENIX GROUP PRICE TARGET TO 688 (667) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES LANCASHIRE HOLDINGS PRICE TARGET TO 693 (667) PENCE - 'EQUAL WEIGHT'----------BARCLAYS RAISES JARDINE LLOYD THOMPSON PRICE TARGET TO 1523 (1495) PENCE - 'OVERWEIGHT'----------BARCLAYS RAISES HISCOX PRICE TARGET TO 1427 (1314) PENCE - 'UNDERWEIGHT'----------BARCLAYS RAISES HASTINGS GROUP PRICE TARGET TO 272 (267) PENCE - 'EQUAL WEIGHT'----------PEEL HUNT RAISES GREENE KING TO 'BUY' ('ADD') - TARGET 700 PENCE----------KEPLER CHEUVREUX RAISES GENUS PRICE TARGET TO 2540 (2470) PENCE - 'HOLD'----------CREDIT SUISSE CUTS WILLIAM HILL PRICE TARGET TO 330 (340) PENCE - 'OUTPERFORM'----------HSBC CUTS WILLIAM HILL PRICE TARGET TO 290 (325) PENCE - 'HOLD'----------OTHER MAIN MARKET AND AIM----------BERENBERG INITIATES GLOBALDATA WITH 'BUY' - TARGET 820 PENCE----------JPMORGAN RAISES REDDE PRICE TARGET TO 207 (197) PENCE - 'OVERWEIGHT'----------PEEL HUNT RESUMES CHEMRING GROUP WITH 'ADD' - TARGET 240 PENCE----------PEEL HUNT RESUMES PAN AFRICAN RESOURCES WITH 'BUY' - TARGET 16 PENCE----------LIBERUM PUTS EI GROUP RATING UNDER REVIEW FROM 'HOLD'----------

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.